このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Oramed Pharmaceuticals 将来の成長

Future 基準チェック /26

Oramed Pharmaceuticalsの収益は年間168.8%で減少すると予測されていますが、年間収益は年間68.6%で増加すると予想されています。EPS は年間167.9%で減少すると予想されています。

主要情報

-168.8%

収益成長率

-167.9%

EPS成長率

Pharmaceuticals 収益成長	27.6%
収益成長率	68.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	29 May 2024

今後の成長に関する最新情報

Recent updates

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Aug 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

May 03

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Dec 22

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Feb 23

Oramed And The Hurdles Of Developing Oral Insulin

Dec 23

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Nov 02

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Oct 04

We Think Shareholders Will Probably Be Generous With Oramed Pharmaceuticals Inc.'s (NASDAQ:ORMP) CEO Compensation

Aug 24

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Jul 21

Oramed reaches 50% enrollment in late-stage oral insulin study

Jun 08

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

Apr 06

The Oramed Pharmaceuticals (NASDAQ:ORMP) Share Price Is Up 110% And Shareholders Are Boasting About It

Feb 12

業績と収益の成長予測

NasdaqCM:ORMP - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	2	-14	N/A	N/A	2
12/31/2024	1	0	N/A	N/A	2
3/31/2024	1	10	-6	-6	N/A
12/31/2023	1	6	-11	-10	N/A
9/30/2023	2	-16	-17	-17	N/A
6/30/2023	3	-20	-19	-18	N/A
3/31/2023	3	-30	-25	-24	N/A
12/31/2022	3	-37	-28	-28	N/A
9/30/2022	3	-46	-39	-39	N/A
6/30/2022	3	-46	-43	-43	N/A
3/31/2022	3	-40	-39	-39	N/A
12/31/2021	3	-35	-33	-33	N/A
11/30/2021	3	-25	-22	-22	N/A
8/31/2021	3	-22	-22	-21	N/A
5/31/2021	3	-18	-18	-17	N/A
2/28/2021	3	-15	-16	-15	N/A
12/31/2020	3	-22	-26	-25	N/A
11/30/2020	3	-15	-16	-16	N/A
8/31/2020	3	-12	-13	-12	N/A
5/31/2020	3	-11	-13	-13	N/A
2/29/2020	3	-13	-14	-14	N/A
11/30/2019	3	-13	-12	-12	N/A
8/31/2019	3	-14	-13	-13	N/A
5/31/2019	3	-15	-14	-14	N/A
2/28/2019	3	-15	-14	-14	N/A
11/30/2018	3	-14	-16	-16	N/A
8/31/2018	2	-13	-15	-15	N/A
5/31/2018	2	-12	-12	-12	N/A
2/28/2018	2	-10	N/A	-11	N/A
11/30/2017	2	-10	N/A	-10	N/A
8/31/2017	2	-10	N/A	-6	N/A
5/31/2017	2	-13	N/A	3	N/A
2/28/2017	2	-13	N/A	3	N/A
11/30/2016	1	-11	N/A	8	N/A
8/31/2016	1	-11	N/A	5	N/A
5/31/2016	0	-8	N/A	-3	N/A
2/29/2016	0	-8	N/A	-2	N/A
11/30/2015	N/A	-8	N/A	-6	N/A
8/31/2015	N/A	-7	N/A	-5	N/A
5/31/2015	N/A	-7	N/A	-5	N/A
2/28/2015	N/A	-7	N/A	-5	N/A
11/30/2014	N/A	-6	N/A	-5	N/A
8/31/2014	N/A	-6	N/A	-4	N/A
5/31/2014	N/A	-5	N/A	-4	N/A
2/28/2014	N/A	-4	N/A	-4	N/A
11/30/2013	N/A	-4	N/A	-3	N/A

アナリストによる今後の成長予測

収入対貯蓄率: ORMPの収益は今後 3 年間で減少すると予測されています (年間-168.8% )。

収益対市場: ORMPの収益は今後 3 年間で減少すると予測されています (年間-168.8% )。

高成長収益: ORMPの収益は今後 3 年間で減少すると予測されています。

収益対市場: ORMPの収益 ( 68.6% ) US市場 ( 8.5% ) よりも速いペースで成長すると予測されています。

高い収益成長: ORMPの収益 ( 68.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ORMPの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Oramed Pharmaceuticals 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus revenue estimates decrease by 50%

Consensus revenue estimates increase by 15%

Consensus EPS estimates fall by 50%

Consensus EPS estimates upgraded to US$0.34 loss

Consensus EPS estimates fall by 13%

Consensus EPS estimates upgraded to US$0.35 loss

Recent updates

Oramed Pharmaceuticals Inc. Appoints Mr. Avraham Gabay as Treasurer and Secretary, Effective as of June 18, 2024

Consensus revenue estimates decrease by 50%

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: EPS: US$0.038 (vs US$0.085 loss in 1Q 2023)

New minor risk - Market cap size

Oramed Pharmaceuticals Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Consensus EPS estimates fall by 50%

Insufficient new directors

Oramed Pharmaceuticals Inc. Appoints Daniel Aghion as Director, Effective January 1, 2024

Third quarter 2023 earnings released: US$0.08 loss per share (vs US$0.18 loss in 3Q 2022)

New minor risk - Market cap size

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Consensus EPS estimates upgraded to US$0.34 loss

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed Pharmaceuticals Inc. (NasdaqCM:ORMP) entered into a Stalking Horse Stock Purchase Term Sheet to acquire a 40.17% stake in Scilex Holding Company (NasdaqCM:SCLX) from Sorrento Therapeutics, Inc. (OTCPK:SRNE.Q) for approximately $110 million.

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Oramed Pharmaceuticals Inc., Annual General Meeting, Jul 13, 2023

Consensus EPS estimates fall by 13%

Consensus EPS estimates upgraded to US$0.35 loss

Price target decreased by 82% to US$2.40

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed Pharmaceuticals (NASDAQ:ORMP) Is In A Good Position To Deliver On Growth Plans

President recently bought US$201k worth of stock

Independent Director recently bought US$142k worth of stock

Consensus EPS estimates upgraded to US$0.59 loss

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased by 23% to US$15.16

Price target decreased to US$21.67

Oramed Pharmaceuticals Inc. Announces Top-Line Results from Phase 3 Trial of ORMD-0801 for the Treatment of Type 2 Diabetes

Oramed Pharmaceuticals Inc. Granted U.S. Combination Therapy Patent for Oral Glp-1 & Insulin for the Treatment of Diabetes

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

Price target decreased to US$28.67

Oramed Announces Additional Positive Safety and Efficacy Data from Its Phase 2 Clinical Trial of ORMD-0801 for NASH

Consensus forecasts updated

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new and inexperienced directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Oramed: Oral Insulin For Type 2 Diabetes May Become A Reality

Oramed Pharmaceuticals Inc. Reports Positive Top-Line Results from Phase 2 Nash Trial with its ORMD-0801, Oral Insulin Candidate

Oramed to hand Korean rights for insulin capsule

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Oramed Reaches 50% Enrollment in Its Second Phase 3 Oral Insulin Trial

High number of new and inexperienced directors

Oramed to report early-stage trial data for oral COVID-19 shot in 3Q

Is Oramed Pharmaceuticals (NASDAQ:ORMP) In A Good Position To Invest In Growth?

Oramed Pharmaceuticals Inc., Annual General Meeting, Jun 30, 2022

Oramed Pharmaceuticals Inc. Appoints Anne Peters to Its Scientific Advisory Board

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Oramed Pharmaceuticals Inc. Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study Ora-D-013-1

Price target increased to US$32.50

Oramed And Oral Insulin: Can This Small Company Really Do It?

Oramed Pharmaceuticals Inc. Grants NASH Patent in Europe

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Independent Chairman of the Board recently sold US$94k worth of stock

Consensus forecasts updated

Companies Like Oramed Pharmaceuticals (NASDAQ:ORMP) Are In A Position To Invest In Growth

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Oramed And The Hurdles Of Developing Oral Insulin

Oramed Subsidiary Oravax Announces First Participant Enrolled in Phase 1 Oral Covid-19 Vaccine Trial in South Africa

Full year 2021 earnings: EPS and revenues miss analyst expectations

Oramed Pharmaceuticals Inc. Reaches 75% Enrollment in Phase 3 Oral Insulin Study

Here's Why We're Not Too Worried About Oramed Pharmaceuticals' (NASDAQ:ORMP) Cash Burn Situation

Oramed: Prospects Still Remain Despite Merck-Ridgeback's Progress

Independent Chairman of the Board recently sold US$443k worth of stock

Independent Director Xiaoming Gao has left the company